JP2010111691A5 - - Google Patents

Download PDF

Info

Publication number
JP2010111691A5
JP2010111691A5 JP2010000195A JP2010000195A JP2010111691A5 JP 2010111691 A5 JP2010111691 A5 JP 2010111691A5 JP 2010000195 A JP2010000195 A JP 2010000195A JP 2010000195 A JP2010000195 A JP 2010000195A JP 2010111691 A5 JP2010111691 A5 JP 2010111691A5
Authority
JP
Japan
Prior art keywords
hydrocarbyl
mixture
aryl
amino
tautomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010000195A
Other languages
English (en)
Japanese (ja)
Other versions
JP5405326B2 (ja
JP2010111691A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2010111691A publication Critical patent/JP2010111691A/ja
Publication of JP2010111691A5 publication Critical patent/JP2010111691A5/ja
Application granted granted Critical
Publication of JP5405326B2 publication Critical patent/JP5405326B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2010000195A 2002-07-24 2010-01-04 ピラゾリルベンゾチアゾール誘導体および治療薬としてのそれらの使用法 Expired - Fee Related JP5405326B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39850402P 2002-07-24 2002-07-24
US60/398,504 2002-07-24

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004523674A Division JP4468810B2 (ja) 2002-07-24 2003-07-23 ピラゾリルベンゾチアゾール誘導体および治療薬としてのそれらの使用法

Publications (3)

Publication Number Publication Date
JP2010111691A JP2010111691A (ja) 2010-05-20
JP2010111691A5 true JP2010111691A5 (https=) 2012-06-07
JP5405326B2 JP5405326B2 (ja) 2014-02-05

Family

ID=31188411

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004523674A Expired - Fee Related JP4468810B2 (ja) 2002-07-24 2003-07-23 ピラゾリルベンゾチアゾール誘導体および治療薬としてのそれらの使用法
JP2010000195A Expired - Fee Related JP5405326B2 (ja) 2002-07-24 2010-01-04 ピラゾリルベンゾチアゾール誘導体および治療薬としてのそれらの使用法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2004523674A Expired - Fee Related JP4468810B2 (ja) 2002-07-24 2003-07-23 ピラゾリルベンゾチアゾール誘導体および治療薬としてのそれらの使用法

Country Status (9)

Country Link
US (4) US7847101B2 (https=)
EP (1) EP1542997B1 (https=)
JP (2) JP4468810B2 (https=)
AT (1) ATE547416T1 (https=)
AU (1) AU2003254650B2 (https=)
CA (1) CA2492964C (https=)
DK (1) DK1542997T3 (https=)
ES (1) ES2385378T3 (https=)
WO (1) WO2004011460A2 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2385378T3 (es) * 2002-07-24 2012-07-24 Dermira (Canada), Inc. Derivados de pirazolilbenzotiazol y su uso como agentes terapéuticos
BRPI0418078A8 (pt) 2003-12-23 2018-01-02 Astex Therapeutics Ltd composto ou um seu sal, solvato, tautômero ou n-óxido, uso de um composto, métodos para a profilaxia ou tratamento de um estado ou condição doentia mediada pela proteína quinase b e mediada pela proteína quinase a, para tratar uma doença ou condição, para inibir uma proteína quinase b e uma proteína quinase a, para modular um processo celular, para tratar um distúrbio imune em um mamífero e para induzir apoptose em uma célula cancerosa, composição farmacêutica, e, processo para a preparação de um composto
EP1902032A1 (en) 2005-06-22 2008-03-26 Astex Therapeutics Limited Pharmaceutical compounds
JP5345842B2 (ja) 2005-06-23 2013-11-20 アステックス・セラピューティクス・リミテッド プロテインキナーゼモジュレーターとしてのピラゾール誘導体を含む医薬組み合わせ
CA2615420A1 (en) * 2005-07-15 2007-01-25 4Sc Ag 2-arylbenzothiazoles and uses thereof
EP1910385B1 (en) * 2005-08-04 2013-07-24 Sirtris Pharmaceuticals, Inc. Benzothiazoles and thiazolopyridines as sirtuin modulators
JP5178515B2 (ja) 2005-08-12 2013-04-10 シンタ ファーマシューティカルズ コーポレーション Hsp90活性を調節するピラゾール化合物
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
TW200911240A (en) * 2007-06-11 2009-03-16 Kyowa Hakko Kogyo Kk Anti-tumor agent
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
BRPI0912892A2 (pt) * 2008-05-21 2016-05-31 Basf Se compostos, processo para a preparação de compostos, composições agroquímicas, método para combater fungos patogênicos, e, semente
MX2010012473A (es) * 2008-05-23 2011-02-23 Siwa Corp Metodos, composiciones y aparato para facilitar la regeneracion.
US8731655B2 (en) 2009-05-12 2014-05-20 Mallinckrodt Llc Compounds containing acyclic N-N bonds for phototherapy
US9186349B2 (en) 2009-05-12 2015-11-17 Mallinckrodt Llc Diaza heterocyclic compounds for phototherapy
CN102482249B (zh) 2009-07-08 2016-06-08 德米拉(加拿大)公司 用于治疗皮肤病症或疾病状态的tofa类似物
US9649376B2 (en) 2010-09-27 2017-05-16 Siwa Corporation Selective removal of age-modified cells for treatment of atherosclerosis
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
BR112013012958A2 (pt) 2010-11-24 2016-07-12 Univ Ohio State Res Found inibidores integrin ligado com quinase
KR20140001965A (ko) * 2010-11-30 2014-01-07 다케다 야쿠힌 고교 가부시키가이샤 바이시클릭 화합물
LT6064B (lt) 2012-10-15 2014-08-25 Vilniaus Universitetas Fluorinti benzensulfonamidai kaip karboanhidrazės inhibitoriai
CN102875486A (zh) * 2012-11-02 2013-01-16 天津希恩思生化科技有限公司 2-苯并恶唑乙腈的制备方法
CN102875541A (zh) * 2012-11-02 2013-01-16 天津希恩思生化科技有限公司 3-(2-苯并恶唑基)-7-羟基香豆素的制备方法
ITMI20132192A1 (it) * 2013-12-23 2015-06-24 Purisa S R L Composti antimicrobici
WO2015127548A1 (en) * 2014-02-28 2015-09-03 The Royal Institution For The Advancement Of Learning / Mcgill University Tc-ptp inhibitors as apc activators for immunotherapy
CN107001459B (zh) 2014-09-19 2021-11-23 Siwa有限公司 用于治疗炎症和自身免疫紊乱的抗age抗体
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
PT3337829T (pt) 2016-02-19 2020-02-10 Siwa Corp Método e composição para o tratamento do cancro, matando células cancerosas metastáticas e prevenindo as metástases do cancro usando anticorpos para produtos finais de glicação avançada (pga)
CA3057829A1 (en) 2016-04-15 2017-10-19 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
WO2017222535A1 (en) 2016-06-23 2017-12-28 Siwa Corporation Vaccines for use in treating various diseases and disorders
GB201617339D0 (en) * 2016-10-12 2016-11-23 Lytix Biopharma As Therapeutic compounds
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
CA3059803A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN113557019B (zh) * 2019-01-18 2026-04-10 Vtv治疗有限责任公司 取代的稠和咪唑衍生物和治疗镰状细胞病和相关并发症的方法
CN111559989B (zh) * 2020-04-12 2022-09-09 青岛科技大学 一种可见光促进2-氨基萘并[2,1-d]噻唑类化合物的合成方法和应用
WO2024003408A1 (en) * 2022-07-01 2024-01-04 Universität Zürich Small-molecule inhibitors of the frs2-fgfr interaction

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52108427A (en) 1976-03-10 1977-09-10 Hodogaya Chem Co Ltd Solubilization of dyes into aromatic hydrocarbon solvent
US4269846A (en) * 1979-10-29 1981-05-26 Usv Pharmaceutical Corporation Heterocyclic compounds useful as anti-allergy agents
US5770592A (en) 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5798349A (en) 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
JP2961074B2 (ja) 1995-09-06 1999-10-12 明治製菓株式会社 光化学療法用の新生血管閉塞剤
US20020168761A1 (en) * 2000-01-24 2002-11-14 Gour Barbara J. Peptidomimetic modulators of cell adhesion
US6043237A (en) 1996-12-10 2000-03-28 Qlt Phototherapeutics, Inc. Use of photodynamic therapy for prevention of secondary cataracts
DE69810938T2 (de) 1997-04-11 2003-11-06 Grelan Pharmaceutical Co., Ltd. Pyrazolderivate und sie enthaltende cox-inhibitoren
US6214819B1 (en) 1998-11-23 2001-04-10 Novartis Ag Method for treating ocular neovascular diseases
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6271233B1 (en) 1999-08-10 2001-08-07 Ciba Vision Corporation Method for treating ocular neovascular diseases
US6436915B1 (en) * 2000-04-07 2002-08-20 Kinetek Pharmaceuticals, Inc. Pyrazole compounds
GB0102687D0 (en) * 2001-02-02 2001-03-21 Pharmacia & Upjohn Spa Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
DK1444233T3 (da) * 2001-11-09 2011-10-17 Gilead Palo Alto Inc A2B-adenosinreceptorantagonister
EP1456180B1 (en) * 2001-12-21 2007-10-03 Vernalis (Cambridge) Limited 3-(2,4)dihydroxyphenyl-4-phenylpyrazoles and their medical use
GB0206860D0 (en) * 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
ES2385378T3 (es) * 2002-07-24 2012-07-24 Dermira (Canada), Inc. Derivados de pirazolilbenzotiazol y su uso como agentes terapéuticos

Similar Documents

Publication Publication Date Title
JP2010111691A5 (https=)
ES2385378T3 (es) Derivados de pirazolilbenzotiazol y su uso como agentes terapéuticos
AU2011227398B2 (en) Modulators of Hec1 activity and methods therefor
ES2510674T3 (es) Inhibidores de la proteína humana tirosina fosfatasa y su uso farmacéutico
JP2020522520A5 (https=)
RU2005138719A (ru) Новые бисамидатные фосфонатные пролекарства
CA2981499A1 (en) Methods of administering glutaminase inhibitors
ES2676585T3 (es) Compuestos heterocíclicos y métodos de uso
JP2010534706A5 (https=)
JP2018519343A5 (https=)
CA2402414A1 (en) Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors
BR112013015260B1 (pt) Derivados de enxofre como moduladores de receptor de quimiocina, composição compreendendo o mesmo e seu uso
JP2010519304A5 (https=)
EP1986633A2 (en) Treatment of duchenne muscular dystrophy
CA2796967A1 (en) Heterocyclic derivatives as alk inhibitors
JP2013545798A5 (https=)
JP2017527532A5 (https=)
RU2013141274A (ru) Содержащие фосфор соединения в качестве ингибиторов протеинкиназ
JP2016529235A5 (https=)
JP2014506582A5 (https=)
JP2018528942A5 (https=)
FI3546462T3 (fi) Uusi oksoisokinoliinijohdannainen
AU2016355429B2 (en) Nucleic acid prodrugs
JP2004525183A5 (https=)
JP2010514733A5 (https=)